


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Henry Chiu et al. Serial No.: 10/614,853 Filed: July 8, 2003 Title: Compositions and Methods for the Treatment of Immune Related Diseases	Group Art Unit: 1647 Examiner: SPECTOR, LORRAINE Confirmation No: 5148 Customer No: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 29, 2006  Aida Guian
--	--

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 C.F.R. §1.126

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated July 21, 2006, please consider the election and remarks.

Election:

Applicants received a Communication from the U.S. Patent and Trademark Office dated July 21, 2006 which contained a requirement for restriction in connection with the application captioned above. More specifically, the Examiner has required a restriction under 35 U.S.C. § 126 of one of the following inventions:

Group I: Claims 1-8, 10 and 11, drawn to nucleic acids, vectors, host cells, expression of protein and fusion proteins, classified in class 435, subclass 69.7 for example;

- Group II: Claims 9 and 11-16, drawn to protein, classified in class 530, subclass 350;
- Group III: Claims 11-16, drawn to protein, classified in Class 530, subclass 387.9;
- Group IV: Claims 13-16, as drawn to antagonists, classification dependent upon species;
- Group V: Claims 17-18, drawn to a method of treatment using protein or agonist, classified in Class 514, subclass 2;
- Group VI: Claims 17-18, as drawn to a method of treatment using an antagonist, classification dependent upon species;
- Group VII: Claims 11-18, as drawn to a method of treatment using an antibody, classified in class, subclass 130.1;
- Group VIII: Claims 19 and 21, drawn to assaying protein using an antibody, classified in class 435, subclass 7.1;
- Group IX: Claims 20, 28 and 29, drawn to a diagnostic assay in which gene expression is detected, classified in Class 435, subclass 6;
- Group X: Claim 22 and 25, drawn to an assay using cells that respond to PRO polypeptides, classified in Class 435, subclass 7.21;
- Group XI: Claim 23 and 24, drawn to an assay using cells that express PRO polypeptides, classified in Class 435, subclass 7.21.